Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was the target of some unusual options trading activity on Wednesday. Stock investors purchased 959 put options on the stock. This represents an increase of 1,179% compared to the typical volume of 75 put options.
Institutional investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Aurinia Pharmaceuticals by 168.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,104 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 3,828 shares during the period. Virtu Financial LLC bought a new position in Aurinia Pharmaceuticals in the 4th quarter valued at about $105,000. Jane Street Group LLC bought a new position in Aurinia Pharmaceuticals in the 3rd quarter valued at about $182,000. Bank of America Corp DE raised its holdings in Aurinia Pharmaceuticals by 8,600.6% in the 4th quarter. Bank of America Corp DE now owns 30,713 shares of the biotechnology company’s stock valued at $210,000 after acquiring an additional 30,360 shares during the period. Finally, Creative Planning raised its holdings in Aurinia Pharmaceuticals by 10.2% in the 4th quarter. Creative Planning now owns 167,657 shares of the biotechnology company’s stock valued at $1,143,000 after acquiring an additional 15,457 shares during the period. 24.30% of the stock is currently owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals stock opened at $6.83 on Thursday. The stock has a market capitalization of $586.73 million, a price-to-earnings ratio of -8.99 and a beta of 1.38. Aurinia Pharmaceuticals has a twelve month low of $5.01 and a twelve month high of $7.85.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.03). The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 8,856.35% and a negative return on equity of 45.80%. On average, equities research analysts anticipate that Aurinia Pharmaceuticals will post -0.62 earnings per share for the current year.
AUPH has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research note on Wednesday, January 9th. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 15th. Cantor Fitzgerald reiterated a “buy” rating and issued a $24.00 target price (up from $18.00) on shares of Aurinia Pharmaceuticals in a research note on Tuesday. Finally, Royal Bank of Canada raised their target price on shares of Aurinia Pharmaceuticals from $9.00 to $11.00 and gave the company a “positive” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $13.75.
WARNING: “Aurinia Pharmaceuticals Target of Unusually Large Options Trading (AUPH)” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2019/03/21/aurinia-pharmaceuticals-target-of-unusually-large-options-trading-auph.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Recommended Story: How to find the components of the quick ratio
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.